Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | Day Return | YTD Return |
---|---|---|---|
All Industries | 100% | 0.03% | 1.28% |
Drug Manufacturers - General | 33.70% | -0.03% | 5.69% |
Healthcare Plans | 13.55% | 0.09% | -4.38% |
Medical Devices | 13.04% | 0.08% | 3.93% |
Diagnostics & Research | 11.52% | -0.02% | 2.11% |
Biotechnology | 11.00% | 0.03% | -9.21% |
Medical Instruments & Supplies | 6.72% | -0.05% | 2.83% |
Medical Care Facilities | 2.87% | -0.04% | 7.19% |
Drug Manufacturers - Specialty & Generic | 2.73% | 0.17% | -7.70% |
Medical Distribution | 2.48% | 0.04% | 11.86% |
Health Information Services | 2.16% | 0.68% | 7.65% |
Pharmaceutical Retailers | 0.24% | 0.02% | -31.95% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
-
Largest Companies in This Sector
Name
|
Last Price
|
1Y Target Est.
|
Market Weight
|
Market Cap
|
Day Change %
|
YTD Return
|
Avg. Analyst Rating
|
---|---|---|---|---|---|---|---|
733.51 | 826.94 | 11.05% |
|
|
|
Buy
|
|
495.35 | 566.61 | 7.22% |
|
|
|
Buy
|
|
146.14 | 173.75 | 5.58% |
|
|
|
Buy
|
|
131.20 | 138.98 | 5.26% |
|
|
|
Buy
|
|
159.62 | 184.70 | 4.48% |
|
|
|
Buy
|
|
573.60 | 616.78 | 3.47% |
|
|
|
Buy
|
|
107.53 | 126.69 | 2.96% |
|
|
|
Buy
|
|
246.58 | 270.66 | 2.89% |
|
|
|
Buy
|
|
269.98 | 306.20 | 2.32% |
|
|
|
Buy
|
|
25.40 | 31.10 | 2.28% |
|
|
|
Buy
|
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
---|---|---|---|---|
139.96 | 41.319B | 0.09% |
|
|
255.32 | 21.195B | 0.10% |
|
|
126.49 | 7.632B | 0.45% |
|
|
83.49 | 7.551B | 0.35% |
|
|
55.53 | 5.76B | 0.40% |
|
Mutual Fund Opportunities
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
---|---|---|---|---|
206.36 | 47.432B | 0.29% |
|
|
87.01 | 47.432B | 0.29% |
|
|
127.79 | 21.195B | 0.10% |
|
|
89.79 | 15.399B | 0.80% |
|
|
92.74 | 15.399B | 0.80% |
|
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
-
Analyst Report: Cronos Group Inc.
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
RatingPrice Target -
Analyst Report: Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
RatingPrice Target -
Analyst Report: Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
RatingPrice Target -
Analyst Report: Walgreens Boots Alliance Inc
Walgreens Boots Alliance Inc. based in Deerfield, Illinois, is a holding company created in December 2014 when Walgreen completed its purchase of privately held Alliance Boots. The company generated $139 billion in FY23 sales. After divesting its healthcare distribution business WBA has presence in more than 9 countries. About 85% of revenue is from the United States. The company has over 14,000 stores under the Walgreen, Duane Reade and Boots names. WBA owns about 16% of Cencora. WBA's fiscal year ends on August 31. The company has reclassified its operations again. The new organization has a United States Retail Pharmacy unit, an International unit, and a U.S. Healthcare segment, which includes recent investments in VillageMD, CareCentrix and Shields Health Solutions.
RatingPrice Target